Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
3.
Clin Exp Dermatol ; 47(12): 2265-2268, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36177874

ABSTRACT

Psoriasis of the external auditory canal (PsEAC) is often under-recognized. The aims of this study were to assess the prevalence of PsEAC, its association with a particular psoriasis subtype and its impact on quality of life (QoL). A prospective study was carried out in two Spanish university hospitals, enrolling consecutive patients who attended a consultation for psoriasis. The clinical features of psoriasis and PsEAC were recorded and the Dermatology Life Quality Index (DLQI) and Itch Numerical Rating Scale (Itch-NRS) were distributed to patients. Overall, 188 of 1000 patients (18.8%) included in the study had PsEAC, which was associated with severity of psoriasis, presence of inverse psoriasis and involvement of the scalp, nails and genitals, but not with obesity or psoriatic arthritis. PsEAC was the main reason for consultation in 27 patients, with itching being the main symptom. In this study, PsEAC had a prevalence of 18.8%. The occurrence of PsEAC was associated with poorer QoL, as measured by DLQI and Itch-NRS.


Subject(s)
Psoriasis , Quality of Life , Humans , Prevalence , Prospective Studies , Ear Canal , Severity of Illness Index , Psoriasis/complications , Pruritus/etiology , Pruritus/complications
4.
Eur J Dermatol ; 32(3): 347-351, 2022 05 01.
Article in English | MEDLINE | ID: mdl-36065543

ABSTRACT

Background: The cause of chondrodermatitis nodularis helicis (CN) (Winkler's disease) is unknown, but potential associations with autoimmune diseases have been suggested in case reports, however, studies with large case series are lacking. Objectives: To clarify the frequency of chronic inflammatory and autoimmune diseases (CADs), and associated gender and age distribution, in a large cohort of patients with CN. Materials & Methods: The frequency of CADs (systemic and cutaneous) was assessed in 215 patients (65.1% males and 34.9% females; median age: 69.6 years) with a histopathological diagnosis of CN (2000-2017). Endocrine diseases were not included. Statistical analysis included Fisher's exact test and multivariate logistic regression analysis. Results: Twenty different CADs were diagnosed in 15.34% patients with CN. The most frequent were polymyalgia rheumatica (six patients), psoriasis (four patients, one with psoriatic arthritis), rheumatoid arthritis (three patients), CREST syndrome (two patients), vitiligo (two patients), and chronic dermatitis (two patients). Several CADs were strongly associated with tobacco smoking. Systemic CADs were more frequent in females (OR: 3.814; CI 1.513-9.613; p = 0.005; multivariate logistic regression analysis). Differences according to age at onset were not significant. Conclusion: We characterize, for the first time, the spectrum of CADs as well as age and gender distribution in patients with CN based on the largest cohort of patients to date. The possible accumulation of different disorders that are strongly associated with tobacco smoking (Buerger's disease, pulmonary Langerhans cell histiocytosis, rheumatoid arthritis, Lupus erythematosus, and others) merits further investigation, but the rarity of some of them makes this challenging.


Subject(s)
Arthritis, Rheumatoid , Autoimmune Diseases , Dermatitis , Aged , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/epidemiology , Autoimmune Diseases/complications , Autoimmune Diseases/epidemiology , Dermatitis/complications , Dermatitis/epidemiology , Female , Humans , Inflammation , Male , Retrospective Studies , Spain/epidemiology
5.
Dermatol Ther ; 35(7): e15583, 2022 07.
Article in English | MEDLINE | ID: mdl-35567525

ABSTRACT

There is limited evidence about the real-world survival of apremilast in patients with psoriasis, especially over the long term. To evaluate the long-term survival of apremilast and its predictive factors when used to treat psoriasis. A retrospective hospital-based study, including data collected from 104 patients. Survival curves were estimated using the Kaplan-Meier estimator. Proportional hazard Cox regression models were used for multivariate analysis. The average duration of the treatment before discontinuation was 28.82 months (95% CI, 22.08-35.57 months) and the median was 12 months (95% CI, 2.68-21.31 months). The retention rates were 51% (1 year), and 33% (5 years). The survival study revealed statistically significant differences between patients with PASI<10 and those in the PASI≥10 group (log-rank test, p < 0.001). The 5-year prevalences were 64% for patients with a PASI of <10 and 5% for those with an index ≥10. In the PASI < 10-patient group, the retention rates were 77% (1 year) and 64% (5 years). Furthermore, 66% of patients who continued apremilast treatment for more than 2 years were receiving off-label doses (30 mg/day). Apremilast may be a suitable and efficient alternative for the treatment of psoriasis patients in the PASI<10 group.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal , Psoriasis , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Humans , Psoriasis/chemically induced , Psoriasis/diagnosis , Psoriasis/drug therapy , Retrospective Studies , Severity of Illness Index , Thalidomide/analogs & derivatives , Treatment Outcome
6.
Medicina (Kaunas) ; 56(11)2020 Oct 30.
Article in English | MEDLINE | ID: mdl-33143166

ABSTRACT

Background and objectives: The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient characteristics. The main objectives of this work are to understand ustekinumab drug survival in patients diagnosed with plaque psoriasis in the Hospital Universitario Central de Asturias (HUCA Dermatology Department, and to identify the predictors of drug discontinuation. Materials and Methods: A retrospective hospital-based study, including data from 148 patients who were receiving ustekinumab (Stelara®) between 1 February 2009 and 30 November 2019, were collected. Survival curves were approximated through the Kaplan-Meier estimator and compared using the log-rank test. Proportional hazard Cox regression models were used for multivariate analyses while both unadjusted and adjusted hazard ratios (HR) were used for summarizing the studied differences. Results: The average duration of the treatment before discontinuation was 47.57 months (SD 32.63 months; median 41 months). The retention rates were 82% (2 years), 66% (5 years), and 58% (8 years). Median survival was 80 months (95% confidence interval. CI 36.9 to 123.01 months). The survival study revealed statistically significant differences between patients with arthritis (log-rank test, p < 0.001) and those who had previously received biological treatment (log-rank test, p = 0.026). The five-year prevalence in patients still under treatment was 80% (those without arthritis) and 54% (arthritis patients). In the multivariate analysis, only the patients with arthritis had a lower rate of drug survival. No statistically significant differences were observed for any of the other comorbidities studied. The first and second most frequent causes of discontinuation were secondary failure and arthritis inefficacy, respectively. Conclusion: Ustekinumab is a biological drug conferring high survival in plaque psoriasis patients. Ustekinumab survival is lower in patients with arthritis.


Subject(s)
Pharmaceutical Preparations , Psoriasis , Adalimumab , Humans , Psoriasis/drug therapy , Retrospective Studies , Treatment Outcome , Ustekinumab/therapeutic use
8.
Head Neck ; 41(5): 1290-1296, 2019 05.
Article in English | MEDLINE | ID: mdl-30537291

ABSTRACT

BACKGROUND: Focal adhesion kinase (FAK) and cortactin overexpression is frequently detected in a variety of cancers, and has been associated with poor clinical outcome. However, there are no data in cutaneous squamous cell carcinoma (cSCC). OBJECTIVE: To investigate the relationship of FAK and cortactin expression with the clinicopathologic features and the impact on the prognosis of cSCC patients. METHODS: FAK and cortactin expression was analyzed by immunohistochemistry on paraffin-embedded tissue samples from 100 patients with cSCC, and correlated with the clinical data. RESULTS: FAK overexpression was a significant risk factor for nodal metastasis with crude and adjusted ratios (HRs) of 2.04, (95% CI [1.08-3.86], [P = 0.029]) and 2.23 (95% CI [1.01-4.91], [P = 0.047]), respectively. Cortactin expression was not a significant risk factor for nodal metastasis. CONCLUSION: These findings demonstrate that FAK overexpression is an independent predictor of nodal metastasis that might be helpful for risk stratification and management of patients with cSCC.


Subject(s)
Biomarkers, Tumor/genetics , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Lymph Nodes/pathology , Skin Neoplasms/metabolism , Squamous Cell Carcinoma of Head and Neck/metabolism , Adult , Aged , Biopsy, Needle , Cohort Studies , Disease-Free Survival , Female , Humans , Immunohistochemistry , Lymphatic Metastasis/pathology , Male , Middle Aged , Predictive Value of Tests , Prognosis , Retrospective Studies , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Squamous Cell Carcinoma of Head and Neck/epidemiology , Squamous Cell Carcinoma of Head and Neck/pathology , Survival Analysis
9.
Arch Dermatol Res ; 310(7): 551-560, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29926164

ABSTRACT

Chondrodermatitis nodularis helicis (CNH) is a benign auricular disease whose differentiation with nonpigmented tumors is mandatory. Clinical characteristics of CNH are well known, but there is no information about the dermoscopic features that could help differentiate CNH from squamous cell carcinoma and other non-melanoma skin cancers. To describe the dermoscopic appearance of CNH and to formulate a differential diagnostic model, we conducted  a retrospective, single center, observational dermoscopic study on a sample of 189 biopsy-proven lesions: 25 CNH; 26 squamous cell carcinomas; 62 basal cell carcinomas and 76 other benign and malignant tumors. Univariate and multivariate analyses were conducted by logistic regression. The most significant dermoscopic finding for CNH was a peculiar global configuration (daisy pattern), consisting of white thick lines, radially arranged, converging to a central rounded yellow/brown clod (an erosion covered by keratin or sero-crust). This pattern achieved 92 and 98% of specificity for discriminating CNH with squamous cell carcinoma and basal cell carcinoma, respectively. In conclusion, dermoscopy is valuable for the diagnosis of CNH as a first screening tool because of a consistent global dermoscopic configuration (daisy pattern), consisting of radially arranged white thick lines surrounding a central rounded yellow/brown clod.


Subject(s)
Carcinoma, Basal Cell/diagnosis , Carcinoma, Squamous Cell/diagnosis , Cartilage Diseases/diagnosis , Dermatitis/diagnosis , Dermoscopy/methods , Skin Neoplasms/diagnosis , Skin/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/pathology , Cartilage Diseases/pathology , Dermatitis/pathology , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Sensitivity and Specificity , Skin Neoplasms/pathology
10.
An Bras Dermatol ; 92(5 Suppl 1): 148-150, 2017.
Article in English | MEDLINE | ID: mdl-29267476

ABSTRACT

Trigeminal trophic syndrome is an uncommon cause of facial ulcers, that affects the sensitive area of the trigeminal nerve. We present the case of an 84-year-old patient with ulcerated facial trigeminal trophic syndrome, and report the development of a clinico-dermoscopic approach for his clinical examination. The value of this model for the diagnosis of facial ulcers suspected to be a rodent ulcer basal cell carcinoma is suggested.


Subject(s)
Carcinoma, Basal Cell/pathology , Facial Dermatoses/pathology , Skin Neoplasms/pathology , Skin Ulcer/pathology , Trigeminal Nerve Diseases/pathology , Aged, 80 and over , Animals , Dermoscopy , Diagnosis, Differential , Humans , Magnetic Resonance Imaging , Male , Syndrome
11.
J Am Acad Dermatol ; 77(3): 527-533, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28716437

ABSTRACT

BACKGROUND: Binding of tumor-expressed programmed cell death ligand 1 (PD-L1) to the programmed cell death 1 (PD-1) surface receptor blocks T-cell activation thereby leading to immune evasion. Tumor PD-L1 expression has been associated with poor outcome in a wide variety of cancers; however, data in cutaneous squamous cell carcinoma (cSCC) are scarce and conflicting. OBJECTIVE: To investigate the relationship of tumor PD-L1 expression with the clinicopathologic features and prognosis of cSCC. METHODS: PD-L1 expression was analyzed by immunohistochemistry on paraffin-embedded tissue samples from 100 patients with cSCC. Cumulative/dynamic receiver operating characteristic curve was used to determine the optimal PD-L1 threshold. Kaplan-Meier estimators and Cox proportional hazards regression models were also used. RESULTS: On the basis of cumulative/dynamic receiver operating characteristic curves, we defined the cut-off score for PD-L1 expression as ≥25% of tumor cells positively stained. PD-L1 expression was a significant risk factor for nodal metastasis with crude and adjusted hazard ratios of 3.39 (1.71-6.65) and 6.54 (2.28-18.78), respectively. LIMITATIONS: This is a retrospective study limited to cSCC of the head and neck. CONCLUSION: These findings indicate that tumor PD-L1 expression predicts increased risk for nodal metastasis in patients with cSCC.


Subject(s)
B7-H1 Antigen/biosynthesis , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/secondary , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Aged , Aged, 80 and over , Female , Humans , Lymphatic Metastasis , Male , Retrospective Studies
12.
An. bras. dermatol ; 92(5,supl.1): 148-150, 2017. graf
Article in English | LILACS | ID: biblio-887082

ABSTRACT

Abstract Trigeminal trophic syndrome is an uncommon cause of facial ulcers, that affects the sensitive area of the trigeminal nerve. We present the case of an 84-year-old patient with ulcerated facial trigeminal trophic syndrome, and report the development of a clinico-dermoscopic approach for his clinical examination. The value of this model for the diagnosis of facial ulcers suspected to be a rodent ulcer basal cell carcinoma is suggested.


Subject(s)
Humans , Animals , Male , Aged, 80 and over , Skin Neoplasms/pathology , Skin Ulcer/pathology , Carcinoma, Basal Cell/pathology , Trigeminal Nerve Diseases/pathology , Facial Dermatoses/pathology , Syndrome , Magnetic Resonance Imaging , Dermoscopy , Diagnosis, Differential
SELECTION OF CITATIONS
SEARCH DETAIL
...